Trials / Conditions / Symptomatic Neurogenic Orthostatic Hypotension

Symptomatic Neurogenic Orthostatic Hypotension

7 registered clinical trials studyying Symptomatic Neurogenic Orthostatic Hypotension.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Mul NCT05696717	Theravance Biopharma	Phase 3
Terminated	Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic NCT04095793	Theravance Biopharma	Phase 3
Terminated	Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic NCT03829657	Theravance Biopharma	Phase 3
Completed	Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Fai NCT03750552	Theravance Biopharma	Phase 3
Completed	Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension NCT02586623	H. Lundbeck A/S	Phase 4
Terminated	A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy NCT01927055	Chelsea Therapeutics	Phase 3
Completed	Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa NCT01149629	Chelsea Therapeutics	Phase 1